Centrum Diagnostyki i Leczenia Nadciśnienia Tętniczego i Cukrzycy dr n. med. Piotr Kubalski
- Address
- lock Available on a paid plan
Centrum Diagnostyki i Leczenia Nadciśnienia Tętniczego i Cukrzycy dr n. med. Piotr Kubalski
The Center for Diagnosis and Treatment of Hypertension and Diabetes, led by Dr. Piotr Kubalski, MD, PhD, is a specialized medical research facility dedicated to advancing the understanding and management of cardiovascular and metabolic disorders. The center focuses on innovative approaches to difficult-to-treat hypertension and comprehensive diabetes care, utilizing state-of-the-art diagnostic techniques including ambulatory blood pressure monitoring (ABPM) to optimize patient outcomes.
- Optimal medical treatment strategies for resistant and difficult-to-treat hypertension using single-pill combination therapies
- Advanced blood pressure monitoring and assessment through 24-hour ambulatory monitoring protocols
- Comparative effectiveness research of antihypertensive medications including spironolactone, eplerenone, and torasemide
- Integrated management of hypertension and diabetes mellitus
The research center conducts rigorous clinical trials examining treatment efficacy in patients with uncontrolled blood pressure, systematically evaluating various triple therapy combinations and fourth-line treatment options. Their evidence-based approach to cardiovascular risk management emphasizes precision medicine, utilizing objective ABPM measurements to guide therapeutic decisions and ensure optimal blood pressure control in challenging patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Agencja Badań Medycznych1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Diagnostyki i Leczenia Nadciśnienia Tętniczego i Cukrzycy dr n. med. Piotr Kubalski
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Eplerenone, Spironolactone, and Torasemide in the Management of Resistant Hypertension in Patients with Uncontrolled Blood Pressure | Agencja Badań Medycznych, Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy | Phase I | Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlodipine | 1 | Unknown | 2023-10-24 | 2023-10-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.